(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 129.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Capricor Therapeutics's revenue in 2025 is $11,130,509.On average, 12 Wall Street analysts forecast CAPR's revenue for 2025 to be $61,674,223, with the lowest CAPR revenue forecast at $0, and the highest CAPR revenue forecast at $288,026,393. On average, 12 Wall Street analysts forecast CAPR's revenue for 2026 to be $4,930,280,344, with the lowest CAPR revenue forecast at $0, and the highest CAPR revenue forecast at $14,377,546,018.
In 2027, CAPR is forecast to generate $5,085,265,974 in revenue, with the lowest revenue forecast at $2,370,137,181 and the highest revenue forecast at $10,400,038,693.